Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 6/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625795 | 0.89 | DRD2 (0.45) | MTNR1BDRD2DRD4DRD1MEN1 | |
| SCHEMBL16625794 | 0.86 | PDE4D (0.44) | MTNR1BPDE4DMEN1KMT2ACYP3A4 | |
| SCHEMBL16625800 | 0.85 | GRIN2C (0.46) | MTNR1BDRD2DRD4 | |
| SCHEMBL12744530 | 0.85 | DRD2 (0.64) | DRD2DRD4DRD1CYP2D6KCNH2 | |
| SCHEMBL16625811 | 0.81 | DRD2 (0.45) | MTNR1BDRD2DRD4PDE4DDRD1 | |
| SCHEMBL328651 | 0.79 | DRD2 (0.69) | MTNR1BDRD2DRD4PDE4DDRD1 | |
| SCHEMBL16627051 | 0.76 | MTNR1B (0.61) | MTNR1BDRD2DRD1MEN1KMT2A | |
| SCHEMBL16625812 | 0.76 | MTNR1B (0.46) | MTNR1BMEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9416632 | 0.74 | DRD2 (0.72) | MTNR1BDRD2PDE4DDRD1CYP3A4 | |
| SCHEMBL16625797 | 0.73 | GRIN2C (0.50) | MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181237-B2 | Substituted berbines and their synthesis | MALLINCKRODT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | SUCAMPO PHARMA AMERICAS LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | TYMS, NME2, TYMP | MTNR1B 3582/4885DRD2 2522/4885DRD4 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.